Calcified coronary lesions are a challenge for percutaneous coronary interventions (PCIs). Coronary intravascular lithotripsy (IVL) is a novel calcium modification technology approved for commercial use in February 2021, but little is known about its uptake in US clinical practice.
Each week, we present a journal club in which we choose a study that we believe will be of interest to the interventional cardiology community and discuss it at a virtual journal club with several of our faculty members.
Panelists
Presenter
